Table 5.
Results of the CERESTIAL trial[45]
| Cabozantinib (n = 470) | Placebo (n = 237) | HR, P-value | |
| OS (M, 95%CI) | 10.2 (9.1-12.0) | 8.0 (6.8-9.4) | HR 0.76 (95%CI 0.63-0.92) P = 0.0049 |
| PFS (M, 95%CI) | 5.2 (4.0-5.5) | 1.9 (1.9-1.9) | HR 0.44 (95%CI 0.36-0.52) P < 0.0001 |
| Objective response (investigator assessed, RECIST 1.1) | |||
| CR (%) | 0 | 0 | |
| PR (%) | 4 | 0.4 | |
| SD (%) | 60 | 33 | |
| PD (%) | 21 | 55 | |
| NE (%) | 15 | 11 | |
| ORR (%, 95CI) | 4 (2.3-6.0) | 0.4 (0.0-2.3) | P = 0.0086 |
| DCR (%) | 64 | 33.4 | |
OS: Overall survival; PFS: Progression-free survival; TTP: Time to progression; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; NE: Not evaluable; ORR: Objective response rate; DCR: Disease control rate.